Alterity Therapeutics Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATHE Nasdaq 2836 alteritytherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alterity Therapeutics Limited

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - Nov 12th, 2025 5:25 am
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System - Nov 10th, 2025 5:25 am
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - Oct 31st, 2025 5:25 am
Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability - Oct 11th, 2025 4:34 pm
Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study - Oct 9th, 2025 6:19 am
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders - Oct 9th, 2025 5:25 am
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders - Oct 2nd, 2025 5:35 am
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Sep 30th, 2025 1:01 pm
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting - Sep 15th, 2025 5:25 am
Alterity Therapeutics Raises A$20.0 million in Strategic Placement - Sep 8th, 2025 5:35 am
Alterity Therapeutics to Present at the Biotech Showcase - Sep 2nd, 2025 5:25 am
We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth - Aug 31st, 2025 5:26 pm
Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy - Aug 16th, 2025 11:56 pm
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report - Jul 30th, 2025 5:25 am
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - Jul 28th, 2025 5:25 am
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study - Jul 24th, 2025 5:25 am
Alterity Therapeutics to Provide Corporate Update in Fireside Chat - Jun 23rd, 2025 5:25 am
Alterity Therapeutics Prominently Featured at the International MSA Congress - May 12th, 2025 5:35 am
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress - May 7th, 2025 6:16 am
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - May 5th, 2025 5:35 am